(Q45074152)

9 December 2017

title

Changes in natural immunity during the course of HIV-1 infection (English)

1 reference

9 December 2017

Brenner BG

1

1 reference

9 December 2017

Gryllis C

series ordinal

2

1 reference

9 December 2017

Gornitsky M

series ordinal

3

1 reference

9 December 2017

Wainberg MA

series ordinal

4

1 reference

9 December 2017

publication date

1 August 1993

1 reference

Clinical and Experimental Immunology

9 December 2017

published in

1 reference

9 December 2017

volume

93

1 reference

9 December 2017

issue

2

1 reference

9 December 2017

page(s)

142-148

1 reference

NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection

9 December 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2249.1993.TB07956.X

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

21 January 2018

1 reference

12 December 2020

Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin

1 reference

12 December 2020

Characterization of HNK-1+ (Leu-7) human lymphocytes. I. Two distinct phenotypes of human NK cells with different cytotoxic capability

1 reference

12 December 2020

Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.

1 reference

12 December 2020

Peripheral blood natural killer cell activity in human breast cancer patients and its modulation by T-cell growth factor and autologous plasma.

1 reference

12 December 2020

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

1 reference

12 December 2020

Lymphokine-activated killer cells. Analysis of progenitors and effectors

1 reference

12 December 2020

Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality

1 reference

12 December 2020

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytot

1 reference

12 December 2020

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

12 December 2020

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

1 reference

12 December 2020

Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals

1 reference

12 December 2020

Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell

1 reference

12 December 2020

Characterization of functional surface structures on human natural killer cells

1 reference

12 December 2020

Selective depletion of low-density CD8+, CD16+ lymphocytes during HIV infection

1 reference

12 December 2020

The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro.

1 reference

12 December 2020

Human natural lymphocyte effector cells: definition, analysis of activity, and clinical effectiveness

1 reference

12 December 2020

Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus

1 reference

12 December 2020

Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins

1 reference

12 December 2020

HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.

1 reference

12 December 2020

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens

1 reference

12 December 2020

Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases

1 reference

12 December 2020

Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation

1 reference

12 December 2020

Lymphokine-activated killer cells in primary immunodeficiencies and acquired immunodeficiency syndrome

1 reference

12 December 2020

Biology of natural killer cells

1 reference

12 December 2020

Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1.

1 reference

12 December 2020

Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects

1 reference

12 December 2020

Cytotoxic T lymphocytes against HIV

1 reference

12 December 2020

Application of flow cytometry to the study of HIV infection

1 reference

12 December 2020

Interleukin-2 in the treatment of HIV disease

1 reference

12 December 2020

Cytotoxic activity against HIV-infected monocytes by recombinant interleukin 2-activated natural killer cells

1 reference

12 December 2020

Biology and clinical relevance of human natural killer cells

1 reference

12 December 2020

In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates

1 reference

12 December 2020

Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp41 synthetic peptides

1 reference

12 December 2020

Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders.

1 reference

12 December 2020

The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-1) infected individuals

1 reference

12 December 2020

Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations

1 reference

12 December 2020

Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression

1 reference

12 December 2020

Tumor-Infiltrating CD3- NK Cells Are More Effective than CD3+ T Cells in Killing Autologous Melanoma Cells

1 reference

12 December 2020

Cytotoxic T-cell recognition of HIV proteins and peptides

1 reference

12 December 2020

Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases

1 reference

12 December 2020

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

12 December 2020

Increased LAK activity against HIV-infected cell lines in HIV-1+ individuals

1 reference

12 December 2020

The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value

1 reference

12 December 2020

Monoclonal antibodies to human lung tumor antigens demonstrated by immunofluorescence and immunoprecipitation

1 reference

12 December 2020

10.1111/J.1365-2249.1993.TB07956.X

Identifiers

DOI

1 reference

9 December 2017

0 references

1 reference